Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
Osteoporos Int
March 2025
World Health Organization (WHO) Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing, University of Liège, Liège, Belgium.
Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations. While randomized controlled trials (RCTs) demonstrate that PTH1 receptor agonists, teriparatide and abaloparatide, are effective at reducing fracture risk, real-world evidence (RWE) remains sparse. This study reviews and compares the anti-fracture efficacy of these agents, against each other and against other osteoporosis treatments using both RCTs and RWE.
View Article and Find Full Text PDFEffects of Sequential Anti-Resorptive Agents on Bone Mineral Density Following Denosumab Withdrawal: A Multicenter Real-World Study in Korea (MAXCARE Study).
Endocrinol Metab (Seoul)
February 2025
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
Background: Denosumab is a potent anti-resorptive agent widely used for osteoporosis. However, its discontinuation results in a 'rebound phenomenon' of rapid bone loss, necessitating transition to alternative anti-resorptive therapies. Despite this, there is limited evidence to guide the selection of the most effective agent, particularly among bisphosphonates.
View Article and Find Full Text PDFChanging trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system.
Osteoporos Int
February 2025
Pharmacy Outcomes Research Group, Kaiser Permanente, Oakland, CA, USA.
Unlabelled: In a single, large integrated US healthcare system, bisphosphonate treatment initiation for fracture prevention among older adults shifted towards higher-risk populations over a 25-year time period (1998-2022). The temporal trends among women and men who initiated treatment reflected changing practice patterns and both primary and secondary fracture prevention efforts.
Introduction: While bisphosphonate (BP) drugs remain first-line for fracture prevention, treatment has changed over time.
Eldecalcitol Add-On to Risedronate Reduces Bone Loss from Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
J Clin Endocrinol Metab
January 2025
Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Context: Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR+EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.
View Article and Find Full Text PDFRisk of glaucoma with bisphosphonate use in patients with osteoporosis: a case-control study.
Eye (Lond)
December 2024
Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada.
Purpose: Bisphosphonates (BPs) are first line agents commonly used in the management of osteoporosis. There have been two case reports that have suggested a possible link between BPs and acute angle closure (AAC). In the absence of any large epidemiologic studies, we sought to determine the risk of AAC and OAG with bisphosphonate use in patients with osteoporosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!